{"product_id":"kras-g12d-peptide-vvvgadgvgk","title":"KRAS G12D Peptide (VVVGADGVGK)","description":"\u003cdiv style=\"max-width:1400px; margin:0 auto; padding:40px 20px; font-family:'Open Sans',sans-serif; font-weight:300; background:#fff; color:#333; font-size:0.95rem; box-sizing:border-box;\"\u003e\n  \u003cdiv style=\"display:flex; flex-direction:column; gap:20px;\"\u003e\n\u003ch2 style=\"margin:0; font-weight:600;\"\u003eKRAS G12D Peptide (VVVGADGVGK) – Catalog #B2026700\u003c\/h2\u003e\n\u003cp\u003eKRAS G12D Peptide (VVVGADGVGK; Catalog #B2026700) is a synthetic, lyophilized 10-amino acid peptide fragment corresponding to a region of the KRAS (Kirsten rat sarcoma viral oncogene homolog) protein that contains the G12D point mutation. With a molecular weight of 900.04 Da and supplied as 1 mg, it serves as an immunogen, capture reagent, or diagnostic control in research focused on KRAS-driven malignancies.\u003c\/p\u003e\n\u003cdiv style=\"overflow-x:auto; max-width:100%; margin-bottom:20px;\"\u003e\n\u003ctable style=\"width:100%; max-width:640px; border-collapse:collapse;\"\u003e\n\u003ctbody\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eCatalog number:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eB2026700\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eLot number:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eBatch dependent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eExpiration Date:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eBatch dependent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eAmount:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003e1 mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003ePeptide sequence:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eVVVGADGVGK\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003e900.04 Da\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eSupplied as:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eLyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eApplications:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eImmunogen for antibody generation, immunoassay calibration and positive control, diagnostic reagent development, cancer research, KRAS mutation detection\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eStorage:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003e−20°C\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eKeywords:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eKRAS G12D peptide, KRAS mutation, KRAS G12D epitope, oncogenic KRAS, KRAS immunogen, KRAS antigen, cancer biomarker peptide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eGrade:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eBiotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity \u0026gt;18 MΩ-cm) and are filtered through 0.22 um.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003ch3 style=\"margin-top:30px;\"\u003eScientific Overview\u003c\/h3\u003e\n\u003cp\u003eKRAS is a small GTPase that acts as a molecular switch controlling cell proliferation, differentiation, and survival. The G12D mutation at codon 12 is one of the most common oncogenic KRAS alterations, accounting for roughly 10–20% of all KRAS mutations in human cancers. This single nucleotide substitution (GGT to GAT) results in replacement of glycine with aspartate at position 12, blocking the intrinsic GTPase activity of KRAS and keeping it locked in the active, GTP-bound state. Consequently, KRAS G12D acts as a dominant oncogene, driving uncontrolled signaling and proliferation in pancreatic, lung, colorectal, and other solid tumors.\u003c\/p\u003e\n\u003cp\u003eKey applications include:\u003c\/p\u003e\n\u003cul style=\"padding-left:20px;\"\u003e\n\u003cli\u003eImmunogen for raising antibodies and monoclonal antibodies specific to KRAS G12D\u003c\/li\u003e\n\u003cli\u003ePositive control in ELISA, immunoassay, and diagnostic assay development\u003c\/li\u003e\n\u003cli\u003eAntigen substrate in KRAS mutation detection and screening assays\u003c\/li\u003e\n\u003cli\u003eResearch into KRAS-driven immune evasion and drug resistance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 style=\"margin-top:30px;\"\u003eUsage \u0026amp; Handling Guidance\u003c\/h3\u003e\n\u003cp\u003eStore the lyophilized powder at −20°C in a tightly sealed container. Upon receipt, briefly centrifuge the vial before opening to collect any powder from the cap and walls. To reconstitute, add appropriate buffer (e.g., PBS or TBS) to the desired concentration. Mix gently and allow the powder to dissolve fully; brief sonication in a water bath may aid dissolution. Prepare single-use aliquots and store at −20°C; repeated freeze–thaw cycles may reduce peptide integrity.\u003c\/p\u003e\n\u003cul style=\"padding-left:20px;\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eReconstitution:\u003c\/strong\u003e Dissolve in sterile buffer appropriate for your assay (e.g., carbonate-bicarbonate buffer for antibody coupling).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImmunization:\u003c\/strong\u003e Consult established immunization protocols; peptide conjugation to a carrier protein (e.g., KLH) may improve immunogenicity.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAssay use:\u003c\/strong\u003e Optimize peptide concentration empirically for your assay platform.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 style=\"margin-top:30px;\"\u003eWhat You Get\u003c\/h3\u003e\n\u003cul style=\"padding-left:20px;\"\u003e\n\u003cli\u003e1 mg of synthetic KRAS G12D peptide (VVVGADGVGK), lyophilized\u003c\/li\u003e\n\u003cli\u003eDefined, reproducible sequence for immunological and diagnostic applications\u003c\/li\u003e\n\u003cli\u003eA toolbox for capturing and detecting KRAS G12D mutations\u003c\/li\u003e\n\u003cli\u003eFor research use only (RUO)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 style=\"margin-top:30px;\"\u003eWhy Researchers Choose It\u003c\/h3\u003e\n\u003cul style=\"padding-left:20px;\"\u003e\n\u003cli\u003eSpecific to the clinically important KRAS G12D hotspot mutation\u003c\/li\u003e\n\u003cli\u003eSmaller than full-length KRAS, making it convenient for coupling and immunization\u003c\/li\u003e\n\u003cli\u003eHomogeneous, synthetic peptide with batch-to-batch consistency\u003c\/li\u003e\n\u003cli\u003eUseful for validating assay performance and detecting KRAS mutations in clinical research\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 style=\"margin-top:30px;\"\u003eFrequently Asked Questions (FAQ)\u003c\/h3\u003e\n\u003cul style=\"padding-left:20px;\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eWhy use this peptide instead of full-length KRAS protein?\u003c\/strong\u003e\u003cbr\u003ePeptides are smaller, easier to handle, more stable, and more cost-effective. They can be coupled directly to carriers or support materials for immunization or assay format.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eWhat carrier should I use for immunization?\u003c\/strong\u003e\u003cbr\u003eCommon carriers include KLH (keyhole limpet hemocyanin) and BSA (bovine serum albumin). Consult published immunization protocols and request technical advice if needed.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHow should I store the reconstituted peptide?\u003c\/strong\u003e\u003cbr\u003eAt −20°C in sterile, sealed tubes. Use fresh aliquots to avoid freeze–thaw degradation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCan this peptide detect KRAS mutations in samples?\u003c\/strong\u003e\u003cbr\u003eThis peptide is an antigen or immunogen. To detect mutations, you would develop antibodies or other binding reagents against this peptide or use it as a capture reagent in an assay format.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCan I get a COA or analytical data?\u003c\/strong\u003e\u003cbr\u003eRequest a quote or contact us and we will provide available lot documentation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cdiv style=\"margin-top:20px; font-weight:bold; color:#c8102e;\"\u003eThis product is for Research Use Only (RUO). It is not intended for diagnostic or therapeutic use in humans or animals.\u003c\/div\u003e\n\u003chr\u003e\n\u003ch4\u003eReferences\u003c\/h4\u003e\n\u003cul style=\"padding-left:0; margin:0; list-style:none;\"\u003e\n\u003cli style=\"display:flex; justify-content:space-between; align-items:flex-start; gap:12px; padding:8px 0; border-bottom:1px solid #eee;\"\u003e\n\u003cspan style=\"flex:1;\"\u003eLiu C, Zheng S, Wang Z, Wang S, Wang X, Yang L, Xu H, Cao Z, Feng X, Xue Q, Wang Y, Sun N, He J. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1\/PD-L1 immunotherapy in non-small cell lung cancer. \u003cem\u003eCancer Commun (Lond).\u003c\/em\u003e 2022;42(9):828-847.\u003c\/span\u003e\u003ca href=\"https:\/\/doi.org\/10.1002\/cac2.12327\" target=\"_blank\" rel=\"noopener\" style=\"flex-shrink:0; margin-top:2px;\"\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0896\/1579\/4474\/files\/Reference.png?v=1775409336\" alt=\"Reference\" style=\"height:28px; width:auto;\"\u003e\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli style=\"display:flex; justify-content:space-between; align-items:flex-start; gap:12px; padding:8px 0; border-bottom:1px solid #eee;\"\u003e\n\u003cspan style=\"flex:1;\"\u003eHallin J, Bowcut V, Calinisan A, Briere DM, Hargis L, Engstrom LD, Laguer J, Medwid J, Vanderpool D, Lifset E, Trinh D, Hoffman N, Wang X, David Lawson J, Gunn RJ, Smith CR, Thomas NC, Martinson M, Bergstrom A, Sullivan F, Bouhana K, Winski S, He L, Fernandez-Banet J, Pavlicek A, Haling JR, Rahbaek L, Marx MA, Olson P, Christensen JG. Anti-tumor efficacy of a potent and selective non-covalent KRAS(G12D) inhibitor. \u003cem\u003eNat Med.\u003c\/em\u003e 2022;28(10):2171-2182.\u003c\/span\u003e\u003ca href=\"https:\/\/doi.org\/10.1038\/s41591-022-02007-7\" target=\"_blank\" rel=\"noopener\" style=\"flex-shrink:0; margin-top:2px;\"\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0896\/1579\/4474\/files\/Reference.png?v=1775409336\" alt=\"Reference\" style=\"height:28px; width:auto;\"\u003e\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli style=\"display:flex; justify-content:space-between; align-items:flex-start; gap:12px; padding:8px 0; border-bottom:1px solid #eee;\"\u003e\n\u003cspan style=\"flex:1;\"\u003eZhou C, Li C, Luo L, Li X, Jia K, He N, Mao S, Wang W, Shao C, Liu X, Huang K, Yu Y, Cai X, Chen Y, Dai Z, Li W, Yu J, Li J, Shen F, Wang Z, He F, Sun X, Mao R, Shi W, Zhang J, Jiang T, Zhang Z, Li F, Ren S. Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer. \u003cem\u003eCancer Cell.\u003c\/em\u003e 2024;42(7):1286-1300.e8.\u003c\/span\u003e\u003ca href=\"https:\/\/doi.org\/10.1016\/j.ccell.2024.06.001\" target=\"_blank\" rel=\"noopener\" style=\"flex-shrink:0; margin-top:2px;\"\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0896\/1579\/4474\/files\/Reference.png?v=1775409336\" alt=\"Reference\" style=\"height:28px; width:auto;\"\u003e\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli style=\"display:flex; justify-content:space-between; align-items:flex-start; gap:12px; padding:8px 0; border-bottom:1px solid #eee;\"\u003e\n\u003cspan style=\"flex:1;\"\u003eStickler S, Rath B, Hamilton G. Targeting KRAS in pancreatic cancer. \u003cem\u003eOncol Res.\u003c\/em\u003e 2024;32(5):799-805.\u003c\/span\u003e\u003ca href=\"https:\/\/doi.org\/10.32604\/or.2024.045356\" target=\"_blank\" rel=\"noopener\" style=\"flex-shrink:0; margin-top:2px;\"\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0896\/1579\/4474\/files\/Reference.png?v=1775409336\" alt=\"Reference\" style=\"height:28px; width:auto;\"\u003e\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n  \u003c\/div\u003e\n\u003c\/div\u003e","brand":"Molecular Depot","offers":[{"title":"Default Title","offer_id":52813633650986,"sku":"BTS-B2026700","price":705.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0896\/1579\/4474\/files\/B2026700.png?v=1790900054","url":"https:\/\/bluetigerscientific.com\/products\/kras-g12d-peptide-vvvgadgvgk","provider":"Blue Tiger Scientific","version":"1.0","type":"link"}